Our comparison showed a general increase in HOX/TALE expression in AML with normal cytogenetics, NPM1 mutations, FLT3 mutations, and 11q23 abnormalities involving the MLL gene while showing an overall decrease in HOX/TALE expression in normal patient CD34+ cells, AML with CEBPA mutations and AML with abnormal cytogenetics, specifically t(15;17), t(8;21), and inv(16). This evidence concerns the gene KMT2A and acute myeloid leukemia.